BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11256141)

  • 1. [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
    Scheen AJ
    Rev Med Liege; 2001 Jan; 56(1):56-8. PubMed ID: 11256141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
    von Haehling S; Lainscak M; Anker SD
    Eur Heart J; 2007 Dec; 28(23):2830-1. PubMed ID: 17984134
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
    Hansen D; Astrup A; Toubro S; Finer N; Kopelman P; Hilsted J; Rössner S; Saris W; Van Gaal L; James W; Goulder M;
    Int J Obes Relat Metab Disord; 2001 Apr; 25(4):496-501. PubMed ID: 11319653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
    Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
    Zhao Y; Wang X; Yan Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):329-32. PubMed ID: 11769634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
    Caterson ID; Finer N; Coutinho W; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Legler UF; Shepherd GM; Rode RA; Perdok RJ; Renz CL; James WP;
    Diabetes Obes Metab; 2012 Jun; 14(6):523-30. PubMed ID: 22192338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
    Andersson C; Weeke P; Fosbøl EL; Brendorp B; Køber L; Coutinho W; Sharma AM; Van Gaal L; Finer N; James WP; Caterson ID; Rode RA; Torp-Pedersen C; ;
    Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
    James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
    N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A; Krause J
    JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome.
    Barkeling B; Elfhag K; Rooth P; Rössner S
    Int J Obes Relat Metab Disord; 2003 Jun; 27(6):693-700. PubMed ID: 12833113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
    Lindholm Å; Bixo M; Björn I; Wölner-Hanssen P; Eliasson M; Larsson A; Johnson O; Poromaa IS
    Fertil Steril; 2008 May; 89(5):1221-1228. PubMed ID: 17603048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.